OCT a good AMD screening tool

Article

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD), according to the results of a study published in the May issue of the British Journal of Ophthalmology.

James Talks and colleagues from the Royal Victoria Infirmary, Newcastle Upon Tyne, UK, carried out a retrospective audit of a consecutive series of 134 new patients referred with suspected wet AMD. If visual acuity (VA) was 6/60, an OCT was performed and if the OCT was consistent with wet AMD, the patient underwent simultaneous fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA). The number of additional diagnoses made using ICGA were recorded.

Twenty-three (17.16%) of the 134 patients had OCT only and were not found to have wet AMD. FFA and ICGA were performed in 111 patients, with 90 patients (81%) showing wet AMD.

OCT had a sensitivity, in this clinic, of 1 and a specificity of 0.65 for detecting wet AMD. ICGA provided additional diagnoses in 19 (14.17%) patients and detected specific vascular abnormalities in 58% of the occult lesions.

Although ICGA can provide an additional diagnosis it does not define vascular abnormalities in all occult cases. OCT, however, has proved to be an effective method of screening wet AMD.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.